Carol Moreno
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research 91
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 59
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments 20
- Immunology top 2%
- Immunodeficiency and Autoimmune Disorders 36
-
- Hormonal Regulation and Hypertension 14
-
- Renin-Angiotensin System Studies 20
-
- Nitric Oxide and Endothelin Effects 12
-
- Eicosanoids and Hypertension Pharmacology 12
- Co-authors
- Emili MontserratRichard J. RomanJozef LazarPaolo GhiaHoward J. JacobMahesh MistryPeter HillmenAlessandra Tedeschi
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Carol Moreno
153 papers receiving 5.4k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Genetics 3.3k
- Pathology and Forensic Medicine 2.6k
- Hematology 934
- Immunology 1.5k
- Endocrinology, Diabetes and Metabolism 630
Countries citing papers authored by Carol Moreno
This map shows the geographic impact of Carol Moreno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Moreno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Moreno more than expected).
Fields of papers citing papers by Carol Moreno
This network shows the impact of papers produced by Carol Moreno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Moreno. The network helps show where Carol Moreno may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Carol Moreno, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 7 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 10 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 1 | |
| 7 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia breakdown → | 2022 | 146 |
| 8 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortbreakdown → | 2022 | 124 |
| 9 | 2021 | 23 | |
| 10 | 2020 | 33 | |
| 11 | 2018 | 2 | |
| 12 | 2018 | 63 | |
| 13 | 2017 | 1 | |
| 14 | Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM) | 2016 | 1 |
| 15 | Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukemia: primary results from the randomised phase IIIb MABLE study | 2015 | 10 |
| 16 | 2011 | 56 | |
| 17 | Liver transplantation for acute liver failure in adults | 2008 | 1 |
| 18 | 2008 | 7 | |
| 19 | 2005 | 50 | |
| 20 | 2005 | 44 |
About Carol Moreno
Carol Moreno is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 155 papers that have together received 5.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (91 papers), Lymphoma Diagnosis and Treatment (59 papers), Immunodeficiency and Autoimmune Disorders (36 papers), Chronic Myeloid Leukemia Treatments (20 papers), Renin-Angiotensin System Studies (20 papers), Hormonal Regulation and Hypertension (14 papers), Nitric Oxide and Endothelin Effects (12 papers) and Eicosanoids and Hypertension Pharmacology (12 papers). The work is most often cited by research in Genetics (3.3k citations), Pathology and Forensic Medicine (2.6k citations) and Hematology (934 citations). Carol Moreno has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Emili Montserrat, Richard J. Roman, Jozef Lazar, Paolo Ghia, Howard J. Jacob, Mahesh Mistry, Peter Hillmen, Alessandra Tedeschi, James P. Dean and Thomas J. Kipps.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.